These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Raising awareness of Raynaud's phenomenon and scleroderma. Mawdsley AH; Brown SJ Nurs Times; 2005 Feb 22-28; 101(8):30-1. PubMed ID: 15754937 [TBL] [Abstract][Full Text] [Related]
3. Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis. Pauling JD; Shipley JA; Harris ND; McHugh NJ Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S103-15. PubMed ID: 22691218 [TBL] [Abstract][Full Text] [Related]
4. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension. Wigley FM Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460 [TBL] [Abstract][Full Text] [Related]
5. The differential diagnosis of Raynaud's phenomenon. Wigley FM Hosp Pract (Off Ed); 1991 Jul; 26(7):63-70, 73-84. PubMed ID: 2071684 [No Abstract] [Full Text] [Related]
9. Role of cold and emotional stress in Raynaud's disease and scleroderma. Freedman RR; Ianni P Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1499-502. PubMed ID: 6416474 [TBL] [Abstract][Full Text] [Related]
10. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon. Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193 [TBL] [Abstract][Full Text] [Related]
11. French translation and linguistic validation of the Raynaud's condition score. Khouri C; Blaise S; Guigui A; Cracowski C; Allanore Y; Hachulla E; Senet P; Roustit M; Cracowski JL Therapie; 2019 Dec; 74(6):627-631. PubMed ID: 31023622 [TBL] [Abstract][Full Text] [Related]